Trial Profile
A Phase III, Prospective, Open-Label, Randomized Clinical Trial Evaluating the Augmenting of Anti-SARS-CoV2 Immunity in Kidney Transplant Recipients Via a Heterologous Additional Dose With Janssen Ad26.CoV2.S Vaccine
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Nov 2023
Price :
$35
*
At a glance
- Drugs Ad26.COV2 S (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- 21 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 08 Apr 2022 Planned initiation date changed from 1 Mar 2022 to 1 May 2022.
- 08 Apr 2022 Status changed from not yet recruiting to recruiting.